Is Arna a good stock to buy now?
ARNA has a Quality Grade of C, ranking ahead of 63.92% of graded US stocks. ARNA's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks. MRSN, CRBP, and ARWR are the stocks whose asset turnover ratios are most correlated with ARNA.
Which stocks have the highest asset turnover ratios for Arna?
MRSN, CRBP, and ARWR are the stocks whose asset turnover ratios are most correlated with ARNA. The table below shows ARNA's key quality metrics over time. For more insight on analysts targets of ARNA, see our ARNA price target page.
Who sold Arena Pharmaceuticals (ARVN) stock?
Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Jayson Donald Alexander Dallas, Robert Lisicki, and Vincent Aurentz. View insider buying and selling activity for Arena Pharmaceuticals or view top insider-selling stocks.
What are Wall Street analysts'target prices for Arena Pharmaceuticals'stock?
12 Wall Street analysts have issued 12-month target prices for Arena Pharmaceuticals' shares. Their forecasts range from $71.00 to $120.00. On average, they expect Arena Pharmaceuticals' stock price to reach $96.67 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
See more
What happens to my Arena Pharmaceuticals stock?
The acquisition was completed by way of a merger in accordance with Delaware law and, as a result of the acquisition, Arena became a wholly-owned subsidiary of Pfizer. In connection with the acquisition, Arena's shares of common stock will be delisted from the Nasdaq Global Select Market on or about March 11, 2022.
Should I buy ARNA stock?
The consensus among Wall Street research analysts is that investors should "hold" Arena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares.
Why did ARNA stock go up?
Covid vaccine maker Pfizer (PFE) said Monday it plans to acquire Arena Pharmaceuticals (ARNA) for $100 a share, in a deal worth an estimated $6.7 billion. The news sent Arena stock rocketing and gave a boost to Pfizer stock.
What is ARNA stock?
ARNA - Arena Pharmaceuticals, Inc. NasdaqGS - NasdaqGS Real Time Price. Currency in USD. 99.99. 0.00 (0.00%)
Why is Pfizer buying arena?
Key Points. Pfizer recently completed a $6.7 billion acquisition of Arena Pharmaceuticals. Pfizer bought Arena Pharmaceuticals to access Etrasimod, an experimental anti-inflammation drug for the treatment of ulcerative colitis and multiple sclerosis.
What is Arena Pharmaceuticals trading at?
(ARNA) Stock Price, News, Quote & History - Yahoo Finance....Performance Outlook.Previous Close99.99Bid0.00 x 800Ask0.00 x 3200Day's Range99.97 - 100.0052 Week Range45.50 - 100.003 more rows
What does Arena Pharmaceuticals make?
Arena's portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including ...
How do I buy Pfizer stock?
Open a brokerage account and place your stock order If you don't already have a brokerage account, you'll need one to buy Pfizer or any other stock. You should look for an online broker that charges no commissions on stock trades, and offers a wide investment selection, low or no fees and good customer service.
Is ARNA stock a buy right now?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 10 hold ratin...
Will Arena Pharmaceuticals' stock price go up in 2022?
10 brokerages have issued 1 year price targets for Arena Pharmaceuticals' shares. Their forecasts range from $71.00 to $105.00. On average, they an...
How were Arena Pharmaceuticals' earnings last quarter?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3...
When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?
Shares of Arena Pharmaceuticals reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June...
Who are Arena Pharmaceuticals' key executives?
Arena Pharmaceuticals' management team includes the following people: Mr. Amit D. Munshi M.B.A. , Pres & CEO (Age 54, Pay $1.22M) Ms. Laurie D....
What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?
16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com . Amit Munshi has an approval rating of 66% among Arena Pharmaceuti...
Who are some of Arena Pharmaceuticals' key competitors?
Some companies that are related to Arena Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regene...
What other stocks do shareholders of Arena Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro...
What is Arena Pharmaceuticals' stock symbol?
Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."
About Arena Pharmaceuticals
Headlines
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P.
Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions
Did The Smart Money Play Arena Pharmaceuticals, Inc. (ARNA) Correctly?
Signals & Forecast
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last twelve months. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arena Pharmaceuticals stock.
Support, Risk & Stop-loss
The Arena Pharmaceuticals stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Is Arena Pharmaceuticals stock A Buy?
Arena Pharmaceuticals finds support from accumulated volume at $92.00 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Arena Pharmaceuticals
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arena Pharmaceuticals stock to perform well in the short-term.
About Arena Pharmaceuticals
In the last 100 trades there were 1.13 million shares bought and 411.79 thousand shares sold. The last trade was done 50 days ago by Aurentz Vincent who bough 21.46 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight management in adults.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Component Grades
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
ARNA POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ARNA Stock Summary
ARNA scores best on the Growth dimension, with a Growth rank ahead of 23.15% of US stocks.
ARNA's Quality Factors
Arena Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 5.55% of US listed stocks.
Latest ARNA News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching ARNA
Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.
What is Stock Sentiment?
Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:
What's Happening With ARNA Stock Today?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
More About Arena Pharmaceuticals, Inc
Arena Pharmaceuticals, Inc. (ARNA) stock is trading at $59.77 as of 2:47 PM on Thursday, Sep 2, a gain of $2.99, or 5.27% from the previous closing price of $56.78. The stock has traded between $56.34 and $60.00 so far today. Volume today is light. So far 421,212 shares have traded compared to average volume of 586,484 shares.
